Quest Diagnostics Incorporated· DGX
🇺🇸 US · LargeSP500NYSE
- Price
- $246.48
- Day
- -0.39%
- Mkt Cap
- $27.20B
- 52W Range
- $171.18 – $248.70
- Volume
- 1.91M
- Beta
- 0.55
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Corient Private Wealth LP decreased its position in Quest Diagnostics Incorporated (NYSE: DGX) by 13.3% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,092 shares of the medical research company's stock after selling 5,233 shares during the period. Corient Private Wealth
Read full article
Fed hikes rates and signals another, putting MGEE, ADM, DOLE and DGX in focus as low-beta defensive picks.
Read full article
Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report)'s stock price hit a new 52-week high on Wednesday. The stock traded as high as $248.65 and last traded at $247.1970, with a volume of 1373537 shares. The stock had previously closed at $237.89. Analyst Ratings Changes A number of brokerages have recently issued reports on
Read full article
75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are scheduled to take effect January 2027 SECAUCUS, N.J., Sept. 16, 2026 /PRNewswire/ -- A new national survey finds the overwhelming majority of American voters rely on diagnostic laboratory testing to guide their healthcare decisions and are deeply concerned about scheduled Medicare payment cuts that could put that access at risk.
Read full article
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read full article
Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript
Read full article
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read full article
Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing directly in the app SECAUCUS, N.J., Sept. 9, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year.
Read full article
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
Read full article
Connor Clark and Lunn Investment Management Ltd. purchased a new position in Quest Diagnostics Incorporated (NYSE: DGX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,113 shares of the medical research company's stock, valued at approximately $660,000. Other
Read full article
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read full article